《新股消息》麦迪卫康(02159.HK)公开发售超购逾167倍 一手中签率15%
内地心脑血管疾病综合医疗营销解决方案市场提供商麦迪卫康(02159.HK)公布招股结果,发售价定於3元,为下限定价(招股价介乎每股3至4元),公开发售录超购167.75倍,经重新分配後,公开发售股数增至50%。每手800股,中签率为15%。该股将於明日(19日)上市。光银国际为独家保荐人。
公司预计集资所得款项净额约为8,930万元,当中约58%将用於拓展公司客户群、疾病覆盖范围及患者群;25%将用於通过开发互联网医院服务补充公司的服务能力;12%将用於运营资金及一般企业用途;5%将用於进一步扩充公司的CRO服务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.